Prognostic relevance of TGF‐β1 and PAI‐1 in cervical cancer
Open Access
- 18 August 2004
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 112 (6) , 1020-1028
- https://doi.org/10.1002/ijc.20512
Abstract
Cervical carcinoma is a human papilloma virus (HPV)-related immunogenic type of malignancy, in which escape of the tumor from the hosts' immune response is thought to play an important role in carcinogenesis. The multifunctional cytokine transforming growth factor-β1 (TGF-β1) is involved in immunosuppression, stroma and extracellular matrix formation and controlling (epithelial) cell growth. The plasminogen activating (PA) system plays a key role in the cascade of tumor-associated proteolysis leading to extracellular matrix degradation and stromal invasion. Changes in expression of components of this system, including plasminogen activator inhibitor-1 (PAI-1), have been associated with poor prognosis in a variety of solid tumors. The present study was undertaken to assess the role of both components on relapse, survival and other clinicopathologic parameters in cervical cancer. The expression of TGF-β1 mRNA in 108 paraffin-embedded cervical carcinomas was detected by mRNA in situ hybridization. Immunohistochemistry was used to investigate the expression of PAI-1 protein. The presence of cytoplasmatic TGF-β1 mRNA in tumor cells was not significantly correlated with the other clinicopathologic parameters investigated or with a worse (disease-free) survival. Expression of the PAI-1 protein in tumor cells was strongly correlated with worse overall and disease-free survival, in addition to well-known prognostic parameters such as lymph node metastasis, depth of tumor infiltration, tumor size and vasoinvasion. In the multivariate analysis, PAI-1 turned out to be a strong independent prognostic factor. In a subgroup of patients without lymph node metastases, PAI-1 was predictive for worse survival and relapse of disease, too. Our results show that the (enhanced) expression of PAI-1 by carcinoma cells is correlated with worse (overall and disease-free) survival of patients with cancer of the uterine cervix. The expression of TGF-β1 in itself is not associated with worse survival in these patients. Although simultaneous presence of the 2 factors was observed in all tumors, induction of PAI-1 by TGF-β1 could not be demonstrated in our group of cervical carcinomas.Keywords
This publication has 53 references indexed in Scilit:
- Upregulation of PAI-1 is mediated through TGF-β/Smad pathway in transplant arteriopathyThe Journal of Heart and Lung Transplantation, 2002
- The Concentration of Serum Transforming Growth Factor Beta-1 (TGF-β1) Is Decreased in Cervical Carcinoma PatientsCancer Investigation, 2002
- Cytokine Profile of Cervical Cancer CellsGynecologic Oncology, 2001
- Aberrant expression of Smad4 results in resistance against the growth‐inhibitory effect of transforming growth factor‐β in the SiHa human cervical carcinoma cell lineInternational Journal of Cancer, 2001
- Endocervical Cancer Is Associated with an Increase in the Ligands and Receptors for Transforming Growth Factor-β and a Contrasting Decrease in p27Kip1Gynecologic Oncology, 2000
- Effects of TGF-β on the immune system: implications for cancer immunotherapyLeukemia, 1999
- The Transcription Factor EGR-1 Suppresses Transformation of Human Fibrosarcoma HT1080 Cells by Coordinated Induction of Transforming Growth Factor-β1, Fibronectin, and Plasminogen Activator Inhibitor-1Journal of Biological Chemistry, 1999
- Quality control of immunohistochemical evaluation of tumour-associated plasminogen activators and related componentsEuropean Journal Of Cancer, 1998
- Tumor-Associated Proteolytic Factors uPA and PAI-1 in Endometrial CarcinomaGynecologic Oncology, 1997
- Transforming growth factor beta inhibits plasminogen activator (PA) activity and stimulates production of urokinase‐type PA, PA inhibitor‐1 mRNA, and protein in rat osteoblast‐like cellsJournal of Cellular Physiology, 1991